FDA approves Regeneron's Pasatru for ultra-rare FOP
STAT reports the FDA approved Regeneron's drug Pasatru for fibrodysplasia ossificans progressiva. This targets ultra-rare disease patients. Long-term real-world outcomes are not yet known.
Why it matters
The FDA approved Pasatru to treat FOP, an ultra-rare disease, per STAT, with long-term real-world outcomes not yet known.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news